Novartis’ Jakavi bests current therapy for GvHD
REACH2 is the first Phase III study in steroid-refractory acute graft-versus-host-disease (GvHD) to have met its primary endpoint
Read More
Tag: REACH2
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
